Javascript must be enabled to continue!
TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis
View through CrossRef
Metabolic dysfunction‐associated steatohepatitis‐driven hepatocellular carcinoma (MASH‐HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions. We previously identified that tumor necrosis factor‐alpha (TNF‐α) upregulated apoptosis antagonizing transcription factor (AATF) in MASH. Here, we investigated the effect of TNF‐α converting enzyme (TACE) inhibition as a promising targeted therapy against AATF‐mediated steatohepatitis to hepatocarcinogenesis. A preclinical murine model that recapitulates human MASH‐HCC was used in the study. C57Bl/6 mice were fed with chow diet normal water (CD) or western diet sugar water (WD) along with a low dose of carbon tetrachloride (CCl4; 0.2 μL·g−1, weekly) for 24 weeks. TACE activity, TNF‐α levels, and AATF expression were measured. The mice were treated with the TACE inhibitor Marimastat for 12 weeks, followed by analyses of liver injury, fibrosis, inflammation, and oncogenic signaling. In vitro experiments using stable clones of AATF control and AATF knockdown were also conducted. We found that AATF expression was upregulated in WD/CCl4 mice, which developed severe MASH at 12 weeks and advanced fibrosis with HCC at 24 weeks. WD/CCl4 mice showed increased TACE activity with reduced hepatic expression of sirtuin 1 (Sirt1) and tissue inhibitor of metalloproteinase 3 (Timp3). The involvement of the SIRT1/TIMP3/TACE axis was confirmed by the release of TNF‐α, which upregulated AATF, a key molecular driver of MASH‐HCC. Interestingly, TACE inhibition by Marimastat reduced liver injury, dyslipidemia, AATF expression, and oncogenic signaling, effectively preventing hepatocarcinogenesis. Furthermore, Marimastat inhibited the activation of JNK, ERK1/2, and AKT, which are key regulators of tumorigenesis in WD/CCl4 mice and in AATF control cells, but had no effect on AATF knockdown cells. This study shows that TACE inhibition prevents AATF‐mediated inflammation, fibrosis, and oncogenesis in MASH‐HCC, offering a potential target for therapeutic intervention.
Title: TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis
Description:
Metabolic dysfunction‐associated steatohepatitis‐driven hepatocellular carcinoma (MASH‐HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions.
We previously identified that tumor necrosis factor‐alpha (TNF‐α) upregulated apoptosis antagonizing transcription factor (AATF) in MASH.
Here, we investigated the effect of TNF‐α converting enzyme (TACE) inhibition as a promising targeted therapy against AATF‐mediated steatohepatitis to hepatocarcinogenesis.
A preclinical murine model that recapitulates human MASH‐HCC was used in the study.
C57Bl/6 mice were fed with chow diet normal water (CD) or western diet sugar water (WD) along with a low dose of carbon tetrachloride (CCl4; 0.
2 μL·g−1, weekly) for 24 weeks.
TACE activity, TNF‐α levels, and AATF expression were measured.
The mice were treated with the TACE inhibitor Marimastat for 12 weeks, followed by analyses of liver injury, fibrosis, inflammation, and oncogenic signaling.
In vitro experiments using stable clones of AATF control and AATF knockdown were also conducted.
We found that AATF expression was upregulated in WD/CCl4 mice, which developed severe MASH at 12 weeks and advanced fibrosis with HCC at 24 weeks.
WD/CCl4 mice showed increased TACE activity with reduced hepatic expression of sirtuin 1 (Sirt1) and tissue inhibitor of metalloproteinase 3 (Timp3).
The involvement of the SIRT1/TIMP3/TACE axis was confirmed by the release of TNF‐α, which upregulated AATF, a key molecular driver of MASH‐HCC.
Interestingly, TACE inhibition by Marimastat reduced liver injury, dyslipidemia, AATF expression, and oncogenic signaling, effectively preventing hepatocarcinogenesis.
Furthermore, Marimastat inhibited the activation of JNK, ERK1/2, and AKT, which are key regulators of tumorigenesis in WD/CCl4 mice and in AATF control cells, but had no effect on AATF knockdown cells.
This study shows that TACE inhibition prevents AATF‐mediated inflammation, fibrosis, and oncogenesis in MASH‐HCC, offering a potential target for therapeutic intervention.
Related Results
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
Background and aims
Angiogenesis is a key factor in the growth and metastasis of hepatic tumors and thus a potential therapeutic target in hepatocellular carcin...
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC), a highly fatal cancer with a mortality rate proportional to its incidence, continues to pose a global health care challenge. Angiog...
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
ABSTRACT
Hepatocellular carcinoma (HCC), a highly fatal cancer with a mortality rate proportional to its incidence, continues to pose a global health care challenge...
Apoptosis Antagonizing Transcription Factor Plays a Dual Role in Remote Preconditioning-Induced Neuroprotection Against Cerebral Ischemia/Reperfusion Injury in Aged Rats
Apoptosis Antagonizing Transcription Factor Plays a Dual Role in Remote Preconditioning-Induced Neuroprotection Against Cerebral Ischemia/Reperfusion Injury in Aged Rats
Abstract
The elderly population is increasingly susceptible to cerebral ischemia/reperfusion (I/R) injury. Although the potential protective effects of remote preconditioni...
Assessment of the feasibility of TACE combined with intratumoral injection of cisplatin in hepatocellular carcinoma
Assessment of the feasibility of TACE combined with intratumoral injection of cisplatin in hepatocellular carcinoma
Abstract
The feasibility of transcatheter arterial chemoembolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcin...
The influence of transarterial chemoembolization on serum levels of soluble programed cell death protein-1 in advanced hepatocellular carcinoma patients
The influence of transarterial chemoembolization on serum levels of soluble programed cell death protein-1 in advanced hepatocellular carcinoma patients
Abstract
Aims
To investigate the implications of soluble programmed cell death protein 1 (sPD-1) in hepatocellular carcinoma (HCC) patients treated with transarterial chem...
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study
ObjectivesThe purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB...
Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG–TGF-β signaling
Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG–TGF-β signaling
Abstract
Hepatocellular carcinoma (HCC), a leading cause of cancer death, has a dynamic and heterogeneous tumor microenvironment (TME) that drives progression and t...

